Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-21 23:04 | 2025-08-19 | SION | Sionna Therapeutics, Inc. | Ridloff Elena | Officer | SELL | $21.62 | 52,000 | $1,124,334 | 71,532 |
| 2025-08-22 04:32 | 2025-08-19 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $15.82 | 4,188 | $66,250 | 104,811 |
| 2025-08-21 23:05 | 2025-08-20 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Director, Officer | OPT+S | $22.75 | 25,000 | $568,750 | 547,343 |
| 2025-08-21 23:15 | 2025-08-19 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $7.01 | 1,100,000 | $7,712,760 | 15,759,075 |
| 2025-08-22 01:46 | 2025-08-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $19.86 | 12,500 | $248,216 | 940,188 |
| 2025-08-22 01:48 | 2025-08-20 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.00 | 1,517 | $30,343 | 927,892 |
| 2025-08-22 00:36 | 2025-08-19 | SPRY | ARS Pharmaceuticals, Inc. | Tanimoto Sarina | Officer, 10% owner | SELL | $14.08 | 50,000 | $703,755 | 1,247,447 |
| 2025-08-21 23:30 | 2025-08-20 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | SELL | $29.18 | 6,492 | $189,437 | 66,270 |
| 2025-08-21 23:30 | 2025-08-19 | LQDA | Liquidia Corp | Horobin Joanna | Director | SELL | $27.17 | 5,000 | $135,850 | 33,755 |
| 2025-08-21 19:00 | 2025-08-19 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.74 | 3,000 | $8,230 | 57,399 |
| 2025-08-21 19:00 | 2025-08-19 | CALC | CalciMedica, Inc. | Hebbar Sudarshan | Officer | BUY | $2.82 | 9,563 | $26,962 | 61,539 |
| 2025-08-22 00:22 | 2025-08-21 | TNXP | Tonix Pharmaceuticals Holding Corp. | Taylor Carolyn E. | Director | BUY | $36.03 | 418 | $15,061 | 418 |
| 2025-08-22 03:44 | 2025-08-21 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $5.34 | 3,401 | $18,161 | 704,591 |
| 2025-08-22 04:03 | 2025-08-19 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $26.59 | 1,573 | $41,826 | 69,340 |
| 2025-08-22 00:44 | 2025-08-21 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer | SELL | $400.18 | 7,616 | $3,047,756 | 109,753 |
| 2025-08-21 23:19 | 2025-08-19 | MGNX | MACROGENICS INC | HEIDEN WILLIAM K | Director | BUY | $1.51 | 100,000 | $150,520 | 111,000 |
| 2025-08-22 00:00 | 2025-08-19 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | OPT+S | $8.67 | 9,300 | $80,618 | 207,213 |
| 2025-08-22 00:05 | 2025-08-19 | INSM | INSMED Inc | Adsett Roger | Officer | SELL | $127.58 | 25,000 | $3,189,585 | 105,637 |
| 2025-08-22 00:07 | 2025-08-20 | INSM | INSMED Inc | SHAROKY MELVIN MD | Director | SELL | $129.50 | 10,000 | $1,295,000 | 274,516 |
| 2025-08-20 23:02 | 2025-08-18 | ALXO | Alx Oncology Holdings Inc. | Shantharam Harish | Officer | BUY | $0.78 | 75,000 | $58,403 | 75,000 |
| 2025-08-20 23:36 | 2025-08-18 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $33.77 | 16,200 | $547,140 | 40,215 |
| 2025-08-20 23:04 | 2025-08-19 | GOSS | Gossamer Bio, Inc. | Milligan Sandra | Director | BUY | $1.92 | 26,050 | $50,016 | 58,050 |
| 2025-08-21 00:14 | 2025-08-19 | ETON | Eton Pharmaceuticals, Inc. | Gruber James R. | Officer | SELL | $16.15 | 41,713 | $673,715 | 204,753 |
| 2025-08-20 23:36 | 2025-08-18 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.02 | 10,983 | $219,906 | 929,409 |
| 2025-08-20 23:13 | 2025-08-18 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $18.24 | 2,805 | $51,158 | 23,970 |
| 2025-08-20 23:11 | 2025-08-18 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $18.24 | 1,683 | $30,695 | 23,948 |
| 2025-08-20 23:12 | 2025-08-18 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $18.24 | 12,126 | $221,154 | 153,470 |
| 2025-08-20 15:11 | 2025-08-18 | PRGO | PERRIGO Co plc | Parker Geoffrey M. | Director | BUY | $22.97 | 4,375 | $100,497 | 9,875 |
| 2025-08-21 01:35 | 2025-08-18 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.99 | 54,728 | $109,160 | 1,919,444 |
| 2025-08-20 23:38 | 2025-08-19 | ZVRA | ZEVRA THERAPEUTICS, INC. | Bode John B | Director | BUY | $9.17 | 5,000 | $45,825 | 45,000 |
| 2025-08-20 23:15 | 2025-08-20 | TNXP | Tonix Pharmaceuticals Holding Corp. | Treco James | Director | BUY | $36.00 | 250 | $9,000 | 250 |
| 2025-08-21 00:13 | 2025-08-18 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.18 | 4,304 | $22,284 | 0 |
| 2025-08-21 00:00 | 2025-08-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.04 | 1,060 | $3,224 | 55,924 |
| 2025-08-21 00:00 | 2025-08-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Schwartz Jonathan David | Officer | SELL | $3.04 | 2,485 | $7,561 | 221,609 |
| 2025-08-21 00:00 | 2025-08-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $3.04 | 1,592 | $4,839 | 135,462 |
| 2025-08-20 23:57 | 2025-08-18 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | OPT+S | $38.21 | 16,389 | $626,171 | 103,613 |
| 2025-08-20 23:28 | 2025-08-18 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $128.40 | 6,865 | $881,470 | 233,924 |
| 2025-08-21 01:12 | 2025-08-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | BAKER BROS. ADVISORS LP | Director | BUY | $380.58 | 97,065 | $36,941,202 | 1,947,968 |
| 2025-08-21 01:09 | 2025-08-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | BAKER BROS. ADVISORS LP | Director | BUY | $364.04 | 68,618 | $24,979,827 | 1,859,091 |
| 2025-08-21 01:14 | 2025-08-18 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $43.98 | 10,000 | $439,776 | 93,466 |
| 2025-08-20 23:42 | 2025-08-18 | ANIP | Ani Pharmaceuticals Inc. | Thoma Jeanne | Director | SELL | $89.15 | 21,540 | $1,920,371 | 23,405 |
| 2025-08-20 23:41 | 2025-08-20 | ANIP | Ani Pharmaceuticals Inc. | Pera Antonio R | Director | SELL | $89.73 | 5,421 | $486,426 | 29,952 |
| 2025-08-19 23:30 | 2025-08-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $75.42 | 27,000 | $2,036,327 | 249,062 |
| 2025-08-20 02:37 | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | Director, Officer | OPT+S | $6.77 | 16,058 | $108,666 | 161,365 |
| 2025-08-20 02:36 | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Officer | OPT+S | $6.77 | 3,766 | $25,485 | 41,931 |
| 2025-08-19 23:12 | 2025-08-15 | ALXO | Alx Oncology Holdings Inc. | Pinto Shelly | Officer | SELL | $0.64 | 611 | $391 | 89,198 |
| 2025-08-20 02:38 | 2025-08-18 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | Officer | OPT+S | $6.77 | 4,365 | $29,538 | 54,858 |
| 2025-08-20 02:40 | 2025-08-18 | BBIO | BridgeBio Pharma, Inc. | Trimarchi Thomas | Officer | SELL | $50.23 | 17,353 | $871,723 | 463,318 |
| 2025-08-19 23:30 | 2025-08-15 | LQDA | Liquidia Corp | Kaseta Michael | Officer | SELL | $26.18 | 20,000 | $523,674 | 356,412 |
| 2025-08-19 23:40 | 2025-08-18 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer | OPT+S | $36.24 | 6,641 | $240,643 | 76,604 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.